Reducing the immunogenicity of fusion proteins
AssigneeMerck Patent GmbH
InventorsStephen D. Gillies, Jeffrey Way, Anita A. Hamilton
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. Compositions and methods of the invention are useful in therapy.
Claims9
-4. (canceled)
A method for reducing the immunogenicity of a fusion protein, the method comprising introducing a glycosylation site within the junction region spanning the fusion junction.
A method for reducing the immunogenicity of a fusion protein, the method comprising introducing a glycosylation site within 10 amino acids of the fusion junction.
-10. (canceled)
-37. (canceled)
Dependencies are inferred from the claim text.